Pulmonary embolism: inpatient and outpatient treatment
https://doi.org/10.21518/2079-701X-2014-12-92-99
Abstract
Pulmonary embolism (PE) is a rather common emergency situation. Occlusion of pulmonary arteries of different calibre may result in critical condition, shock, sudden death, while in a number of patients who survived thromboembolism it may lead to long-term complications of varying severity: post-thromboembolic chronic pulmonary hypertension, changes in respiratory biomechanics and respiratory failure, and so on. In most cases blood clots enter the pulmonary arterial tree (up to 90% of cases) from the venous system of the lower extremities, pelvis, kidney, and quite rarely from the right side of the heart and the venous system of the upper extremities [1].
Keywords
тромбоэмболия легочной артерии,
тромбоз глубоких вен,
венозные тромбоэмболические осложнения,
антикоагулянты,
варфарин,
дабигатрана этексилат,
ривароксабан,
pulmonary embolism,
deep vein thrombosis,
venous thromboembolic complications,
anticoagulants,
warfarin,
dabigatran etexilate,
rivaroxaban,
apixaban
About the Authors
GE Gendlin
the Pirogov Russian National Research Medical University, Moscow
Russian Federation
Russian Federation
А. AV Melekhov
the Pirogov Russian National Research Medical University, Moscow
Russian Federation
Russian Federation
GI Storozhakov
the Pirogov Russian National Research Medical University, Moscow
Russian Federation
Russian Federation
EE Ryazantseva
the Pirogov Russian National Research Medical University, Moscow
Russian Federation
Russian Federation
References
1. Российские клинические рекомендации по диагностике, лечению и профилактике венозных тромбоэмболических осложнений. Флебология, 2010, 4, 2(1): 1-37.
2. Guidelines on the diagnosis and management of acute pulmonary embolism. European Heart Journal, 2008, 29: 2276-2315.
3. Spirk D, Husmann M, Hayoz D, Baldi T et al. Predictors of in-hospital mortality in elderly patients with acute venous thrombo-embolism: the SWIss Venous ThromboEmbolism Registry (SWIVTER). European Heart Journal, 2012, 33: 921-926.
4. Beckman MG, Hooper WC, Critchley SE, Ortel TL. Venous Thromboembolism. A Public Health Concern. Am J Prev Med, 2010, 38(4S): 495-501.
5. Spencer FA, Lessard D, Emery C, Reed G et al. Venous Thromboembolism in the Outpatient Setting. Arch Intern Med, 2007, 23, 167(14): 1471-1475.
6. Sweetland S, Green J, Liu B, de Gonzalez AB et al. Duration and magnitude of the postoperative risk of venous thromboembolism in middle aged women: prospective cohort study. BMJ, 2009, 3, 339: b4583.
7. Воробьева Н.А., Пономарева И.А. Венозный тромбоэмболизм - мифы и реальность. Трудный пациент, 2009, 6-7: 29-36.
8. Le Cal, Righini M, Roy PM, Sanches O et al. Prediction of pulmonary embolism in the emergency department: the revised Geneva score. Ann Intern Med, 2006, 7, 144 (3): 165-171.
9. Багрова И.В., Кухарчик Г.А., Серебрякова В.И., Константинова И.В., Капутин М.Ю. Современные подходы к диагностике тромбоэмболии легочной артерии. Флебология, 2012, 4: 35-42.
10. Valid U, Singer E, Marhefka GD, Kraft WK et al. Poor Positive Predictive Value of McConnells Sign on Transthoracic Echocardiography for the Diagnosis of Acute Pulmonary Embolism. Hospital Practice, 2013, 41, 3: 2154-8331.
11. Powell BP, Simes D. Levosimendan in acute pulmonary embolism. Anaesth Intensive Care, 2007, 35(5): 771-772.
12. Turpie AG. Oral, direct factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases. Thromb. Vasc. Biol. 2007, 27: 1238-1247.
13. Bauersachs R et al. Oral Rivaroxaban for Symptomatic Venous Thromboembolism. N Engl J Med., 2010, 23, 363(26): 2499-2510.
14. Buller HR, Prins MH, Lensing AWA, Decousus H et al. Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism. N Engl J Med, 2012, 366: 1287-1297.
15. Agnelli G, Gallus A, Goldhaber SZ, Haas S et al. Treatment of Proximal Deep-Vein Thrombosis With the Oral Direct Factor Xa Inhibitor Rivaroxaban (BAY 59-7939): The ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) Study. Circulation July 10, 2007, 116: 180-187.
16. Prins MH, Lensing A, Bauersachs R, van Bellen B et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thrombosis Journal, 2013, 11, 21. http://wwwthrombosisjournal. com/content/11/1/21.
17. Van Es J, Douma RA, Kamphuisen PW, Gerdes VE et al. Clot resolution after 3 weeks of anticoagulant treatment for pulmonary embolism: comparison of computed tomography and perfusion scintigraphy J Thromb Haemost., 2013, 11: 679-685.
Review
For citations:
Gendlin G, Melekhov A, Storozhakov G, Ryazantseva E. Pulmonary embolism: inpatient and outpatient treatment. Meditsinskiy sovet = Medical Council. 2014;(12):92-99. (In Russ.) https://doi.org/10.21518/2079-701X-2014-12-92-99
Views:
548
Email this article 